StockData
Standard BioTools Inc. logo

Standard BioTools Inc. (LAB) stock

LABNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 12/3087% below fair value
$0.54−0.08 (-13.14%)

Close on Nov 17, 2026Market cap $211.76MP/E 2.5Yield –

Standard BioTools operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Standard BioTools's operating income for the twelve months ending Jun 30, 2026 was -$95.47M. For fiscal 2025 it was -$110.25M. The highest annual figure on record is -$14.57M in fiscal 2010.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$110.25M–
FY2024Dec 31, 2024-$127.49M–
FY2023Dec 31, 2023-$76.60M–
FY2022Dec 31, 2022-$116.21M–
FY2021Dec 31, 2021-$67.46M–
FY2020Dec 31, 2020-$51.04M–
FY2019Dec 31, 2019-$51.84M–
FY2018Dec 31, 2018-$48.16M–
FY2017Dec 31, 2017-$58.36M–
FY2016Dec 31, 2016-$73.19M–
FY2015Dec 31, 2015-$50.16M–
FY2014Dec 31, 2014-$51.84M–
FY2013Dec 31, 2013-$18.65M–
FY2012Dec 31, 2012-$18.07M–
FY2011Dec 31, 2011-$18.57M–
FY2010Dec 31, 2010-$14.57M–
FY2009Dec 31, 2009-$18.04M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$25.39M–
Q1 FY2026Mar 31, 2026-$12.50M–
Q4 FY2025Dec 31, 2025-$24.64M–
Q3 FY2025Sep 30, 2025-$32.94M–
Q2 FY2025Jun 30, 2025-$25.70M–
Q1 FY2025Mar 31, 2025-$26.97M–
Q4 FY2024Dec 31, 2024-$26.08M–
Q3 FY2024Sep 30, 2024-$26.70M–
Q2 FY2024Jun 30, 2024-$30.26M–
Q1 FY2024Mar 31, 2024-$60.18M–
Q4 FY2023Dec 31, 2023-$21.39M–
Q3 FY2023Sep 30, 2023-$21.17M–
Q2 FY2023Jun 30, 2023-$17.45M–
Q1 FY2023Mar 31, 2023-$16.59M–
Q4 FY2022Dec 31, 2022-$21.11M–
Q3 FY2022Sep 30, 2022-$29.03M–
Q2 FY2022Jun 30, 2022-$38.56M–
Q1 FY2022Mar 31, 2022-$27.50M–
Q4 FY2021Dec 31, 2021-$11.26M–
Q3 FY2021Sep 30, 2021-$19.61M–
Q2 FY2021Jun 30, 2021-$17.27M–
Q1 FY2021Mar 31, 2021-$19.32M–
Q4 FY2020Dec 31, 2020-$16.90M–
Q3 FY2020Sep 30, 2020-$5.46M–
Q2 FY2020Jun 30, 2020-$13.73M–
Q1 FY2020Mar 31, 2020-$14.94M–
Q4 FY2019Dec 31, 2019-$9.18M–
Q3 FY2019Sep 30, 2019-$13.82M–
Q2 FY2019Jun 30, 2019-$14.64M–
Q1 FY2019Mar 31, 2019-$14.21M–
Q4 FY2018Dec 31, 2018-$11.12M–
Q3 FY2018Sep 30, 2018-$11.63M–
Q2 FY2018Jun 30, 2018-$12.79M–
Q1 FY2018Mar 31, 2018-$12.63M–
Q4 FY2017Dec 31, 2017-$8.74M–
Q3 FY2017Sep 30, 2017-$15.60M–
Q2 FY2017Jun 30, 2017-$16.49M–
Q1 FY2017Mar 31, 2017-$17.54M–
Q4 FY2016Dec 31, 2016-$17.70M–
Q3 FY2016Sep 30, 2016-$18.48M–

More Standard BioTools figures

See a number that looks wrong?